Recent

% | $
Quotes you view appear here for quick access.

Lexicon Pharmaceuticals, Inc. Message Board

  • pkornie@sbcglobal.net pkornie Oct 18, 2011 9:37 AM Flag

    Re: LEXGE.OB

    << http://finance.yahoo.com/q/ta?t=5d&s=LEXGE.OB&l=on&z=l&q=l&c= >>

    HOLDyoLXRN.OBforever+GiveToOTHERb.
    HOLDyoLEXG.OB_Oh....Wait_a_Second-youCan't.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • pkornie@sbcglobal.net pkornie Aug 20, 2012 6:48 PM Flag

      http://finance.yahoo.com/q?s=LEXG

      http://finance.yahoo.com/q?s=LEXG

      Sub.50 ForHowLongNow.

      Q.

      .

      .(___Q___).

      If'u'DieFromAIDS-GiveToOtherB(Buy)GILDY.

      o.

      .

      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>

      << http://finance.yahoo.com/q/ta?t=1d&s=GIL... >>

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=my&l=on&z=l&q=l&p=b%2Cs&a=&c=lexg%2Clxrx%2Clxrx.ob%2Clexg.ob >>


      << http://finance.yahoo.com/q/ta?s=GILD&t=m... >>

      .(___Q___).

      o.

      .

      Sentiment : Hold

      Q.

      .

    • pkornie@sbcglobal.net pkornie Aug 16, 2012 12:27 PM Flag

      .(___Q___).

      If'u'DieFromAIDS-GiveToOtherB(Buy)GILDY.

      o.

      .

      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>

      << http://finance.yahoo.com/q/ta?t=1d&s=GIL... >>

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=my&l=on&z=l&q=l&p=b%2Cs&a=&c=lexg%2Clxrx%2Clxrx.ob%2Clexg.ob >>


      << http://finance.yahoo.com/q/ta?s=GILD&t=m... >>

      .(___Q___).

      o.

      .

    • pkornie@sbcglobal.net pkornie Jul 30, 2012 2:07 AM Flag

      << Thank you!
      Hello PINK,
      Thank you for contacting Yahoo! Customer Care.
      •If you are reporting abuse,... complete our investigation.
      •If you are submitting a request for assistance, or asking a question, we ...
      Sincerely,
      The Yahoo! Customer Care Team
      Yahoo! may, in appropriate circumstances and as its sole discretion, terminate, or take other action on, the accounts of users who appear to have violated the Yahoo! Terms of Service. However, under Yahoo! Terms of Service and our Privacy Policy, we are unable to disclose any action taken on another user’s account.
      Close. >>
      << .(___Q___).
      ____________.... ... . . xxx

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>
      << http://finance.yahoo.com/q?s=LEXGE >>
      WhenIs'O'gettingBusted.O.
      .Changed Ticker Symbol
      LEXGE.OB is no longer valid. It has changed to LEXGE.
      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>
      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>
      << http://finance.yahoo.com/q/ta?s=LEXG&t=1... >>
      << http://investors.gilead.com/phoenix.zhtm... >>
      << http://investors.gilead.com/phoenix.zhtm... >>
      << http://messages.finance.yahoo.com/Stocks... >>
      o.
      .
      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth
      DOW JONES NEWSWIRES
      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.
      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com
      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>
      Sentiment : Strong Buy
      Sentiment : Strong Buy
      >>
      Sentiment : Strong Buy
      Sentiment : Hold Rating :
      o.
      .
      Sentiment : Hold
      Sentiment : You_Hold_B.(_O_).
      o.
      .
      Sentiment : Hold
      Sentiment : Hold
      Sentiment : Hold >>

    • pkornie@sbcglobal.net pkornie Jul 26, 2012 10:29 AM Flag

      .(___Q___).
      ____________.... ... . . xxx

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>

      << http://finance.yahoo.com/q?s=LEXGE >>

      WhenIs'O'gettingBusted.O.

      .Changed Ticker Symbol
      LEXGE.OB is no longer valid. It has changed to LEXGE.

      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>

      << http://finance.yahoo.com/q/ta?s=LEXG&t=1... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://messages.finance.yahoo.com/Stocks... >>

      o.

      .

      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

      Sentiment : Strong Buy

      Sentiment : Hold Rating :

      o.

      .

      Sentiment : Hold

      Sentiment : You_Hold_B.(_O_).

      o.

      .

      Sentiment : Hold

      Sentiment : Hold

    • pkornie@sbcglobal.net pkornie Jul 15, 2012 2:04 AM Flag

      << http://finance.yahoo.com/q?s=LEXGE >>

      WhenIs'O'gettingBusted.O.

      .Changed Ticker Symbol
      LEXGE.OB is no longer valid. It has changed to LEXGE.

      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>

      << http://finance.yahoo.com/q/ta?s=LEXG&t=1... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://messages.finance.yahoo.com/Stocks... >>

      o.

      .

      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

      Sentiment : Strong Buy

      Sentiment : Hold Rating :

      o.

      .

      Sentiment : Hold

      Sentiment : You_Hold_B.(_O_).

      o.

      .

    • pkornie@sbcglobal.net pkornie Jun 24, 2012 3:35 AM Flag

      << http://finance.yahoo.com/q/ta?s=GILD&t=1... >>

      << hffp://finance.yahoo.com/q/ta?s=GILD&t=1d&l=on&z=l&q=l&p=b&a=&c= >>

      << http://finance.yahoo.com/q/ta?s=LEXG&t=1... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://investors.gilead.com/phoenix.zhtm... >>

      << http://messages.finance.yahoo.com/Stocks... >>

      o.

      .

      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

      Sentiment : Strong Buy

      Sentiment : Hold Rating :

      o.

      .

    • pkornie@sbcglobal.net pkornie Jun 19, 2012 10:47 AM Flag
    • pkornie@sbcglobal.net pkornie Jun 16, 2012 7:49 PM Flag

      << http://investors.gilead.com/phoenix.zhtml?p=irol-eventDetails&c=69964&eventID=4791207 >>

      << http://investors.gilead.com/phoenix.zhtml?p=irol-eventDetails&c=69964&eventID=4791207 >>

      << http://messages.finance.yahoo.com/Stocks... >>

      o.

      .

      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

      Sentiment : Strong Buy

      Sentiment : Hold Rating :

      o.

      .

    • pkornie@sbcglobal.net pkornie Jun 7, 2012 11:32 AM Flag

      << http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_L/threadview?m=tm&bn=95699&tid=5073&mid=5087&tof=1&rt=2&frt=2&off=1 >>

      o.

      .

      MEXICON_PHARMACUTICALS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

      Sentiment : Strong Buy

      Sentiment : Hold Rating :
      (No ratings)

    • View More Messages
 
LXRX
8.14-0.59(-6.76%)4:00 PMEST